2-methoxyestradiol enhances p53 protein transduction therapy-associated inhibition of the proliferation of oral cancer cells through the suppression of NFkappaB activity

Acta Med Okayama. 2004 Aug;58(4):181-7. doi: 10.18926/AMO/32086.

Abstract

Protein transduction therapy using poly-arginine peptide can deliver the biologically active proteins. A previous study showed that 11 poly-arginine fused p53 protein (11R-p53) effectively penetrated across the plasma membrane and inhibited the proliferation of oral cancer cells. However, the intracellular half-life of the delivered protein was less than 36 h. Previous studies also showed that 2-methoxyestradiol (2-ME), an endogenous non-toxic estrogenic metabolite, induces the stabilization of the wild-type p53 protein in human cancer cells posttranscriptionally. In the present study, we examined whether 2-ME induced the stabilization of 11R-p53 and had an inhibitory effect on the proliferation of oral cancer cells. The application of 2-ME significantly enhanced the inhibitory effect of 11R-p53 on the proliferation of oral cancer cells. However, 2-ME had no effect on the intracellular half-life of 11R-p53 in oral cancer cells. Of interest is the finding that 2-ME suppressed the transcriptional activity of NFkappaB, which has an important role in tumorigenesis, but did not affect p53 transcriptional activity. These results suggest that 2-ME synergistically enhances the 11R-p53-induced inhibition of the proliferation of oral cancer cells through the suppression of NFkB transcription.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Methoxyestradiol
  • Carcinoma, Squamous Cell*
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cell Membrane / metabolism
  • Drug Therapy, Combination
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology*
  • Humans
  • Mouth Neoplasms*
  • NF-kappa B / metabolism*
  • Peptides / genetics
  • Peptides / pharmacokinetics
  • Recombinant Fusion Proteins / pharmacokinetics
  • Transcription, Genetic / drug effects
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / pharmacokinetics*

Substances

  • NF-kappa B
  • Peptides
  • Recombinant Fusion Proteins
  • Tumor Suppressor Protein p53
  • polyarginine
  • Estradiol
  • 2-Methoxyestradiol